Schizophrenia: all 3,539 studies

Page 28 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• Effects of Ketamine and Risperidone on CognitionCompletedNCT01140620Phase 4
• The Evaluation of Therapeutic Efficacy on the Integrated Group Psychotherapy for Patients With SchizophreniaCompletedNCT01139099Not applicable
• Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)CompletedNCT01138618
• The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic PatientsTerminatedNCT01137799Phase 1
• Patient Guided Psychiatric AdmissionsCompletedNCT01133587Not applicable
• Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled StudyStatus unknownNCT01133080Phase 4
• A Long-Term, Open-Label, Study on SchizophreniaTerminatedNCT01129674Phase 2/3
• Promoting Adherence to Treatment in SchizophreniaCompletedNCT01125267Not applicable
• Clozapine and Olanzapine Treatment of AggressionCompletedNCT01123408Not applicable
• Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without SchizophreniaWithdrawnNCT01123317Not applicable
• Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in SchizophreniaCompletedNCT01121042Phase 3
• A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective DisorderCompletedNCT01116830Phase 1
• A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone PalmitateCompletedNCT01110317Phase 1
• Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic PatientsCompletedNCT01105481Phase 4
• Ketamine Challenge Study With JNJ-40411813CompletedNCT01101659Phase 1
• Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With SchizophreniaCompletedNCT01095562Phase 2
• A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective DisorderCompletedNCT01094249Phase 1
• Effect of Varenicline on Cognitive Function in Cigarette Smokers With SchizophreniaCompletedNCT01093365Phase 2
• Factors Association With Poor Physical Function in Older Adults With SchizophreniaCompletedNCT01092598
• A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia PatientsCompletedNCT01091506Not applicable
• Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy SubjectsCompletedNCT01090440Phase 1
• A Comparator Study of LY2140023 Versus Placebo in Schizophrenia PatientsCompletedNCT01086748Phase 2
• Is MS14 Helpful in Schizophrenia?Status unknownNCT01083381Phase 2
• Digoxin Drug-Drug Interaction With Lurasidone HClCompletedNCT01082289Phase 1
• Midazolam Drug-Drug Interaction Study With Lurasidone HClCompletedNCT01082263Phase 1
• The Bioequivalence Of Two Different Lurasidone Formulations In PatientsCompletedNCT01082250Phase 1
• Assertive Community Treatment (ACT) in Schizophrenia Spectrum DisordersCompletedNCT01081418Phase 4
• Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk GenotypeStatus unknownNCT01078870Phase 4
• Cognitive Remediation Therapy and SchizophreniaCompletedNCT01078129Not applicable
• A Study of a Remediation Program of Social Cognition in SchizophreniaTerminatedNCT01077791Phase 2
• Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With SchizophreniaCompletedNCT01077700Phase 2
• Expanding Rapid Ascertainment Networks of Schizophrenia Families in TaiwanCompletedNCT01077687
• A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological DifferentiationsStatus unknownNCT01075373
• Prevention of Weight Gain in Early PsychosesCompletedNCT01075295Not applicable
• Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HClCompletedNCT01074632Phase 1
• Lithium Drug-Drug Interaction Study With Lurasidone HClCompletedNCT01074073Phase 1
• Quetiapine XR in Schizophrenic PatientsTerminatedNCT01071135Phase 3
• Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in SchizophreniaCompletedNCT01066403Not applicable
• Imaging Cannabinoid CB1 Receptors in SchizophreniaTerminatedNCT01063335
• A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy MenCompletedNCT01060228Phase 1
• Standard Comprehensive Intervention to Treat First-episode SchizophreniaStatus unknownNCT01057849Not applicable
• Compensatory Strategies Applied to Cognitive Impairment in SchizophreniaCompletedNCT01055509Not applicable
• Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of SchizophreniaCompletedNCT01052389Phase 4
• A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With SchizophreniaCompletedNCT01051531Phase 3
• Treatment of N-methyl-D-aspartate (NMDA) Enhancers for SchizophreniaCompletedNCT01047592Phase 2
• Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and QuetiapineStatus unknownNCT01047215Phase 4
• fMRI Study of Nicotinic Effect on Neurophysiology of SchizophreniaCompletedNCT01046526
• Family-based Genetic Long-term Study of Brain Function in SchizophreniaStatus unknownNCT01045824
• The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in SchizophreniaStatus unknownNCT01045720Phase 2
• Competence Ability Study in People With SchizophreniaStatus unknownNCT01045629
• Genes, Intermediate Phenotypes and Response to Quetiapine RXCompletedNCT01044914
• Pharmacokinetic Study of ABT-126 in Stable Subjects With SchizophreniaCompletedNCT01043458Phase 1
• Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia PatientsCompletedNCT01043250
• Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal WomenCompletedNCT01041092Phase 4
• Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug DependenceCompletedNCT01037075
• Neuroimaging Studies of Neurophysiological Phenotypes in SchizophreniaCompletedNCT01036568
• Cognitive Skills Training Using Computer for Patients With Severe Mental IllnessCompletedNCT01036282Phase 4
• Dopamine Function and Reward Processing In SchizophreniaCompletedNCT01035996
• Effects of Nicotine on Areas of Impaired and Preserved Functioning in SchizophreniaCompletedNCT01034085
• Risk Perception in Drug-Dependent Adults With and Without SchizophreniaCompletedNCT01031563
• Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual RealityCompletedNCT01031433
• Metacognitive Training in SchizophreniaCompletedNCT01029067Not applicable
• Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or DepressionCompletedNCT01028196
• InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral AntipsychoticsCompletedNCT01026285
• High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled StudyCompletedNCT01022489Phase 2/3
• Identifying Predictors of Response to Antipsychotics Using a Treatment AlgorithmStatus unknownNCT01016145Phase 4
• A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With ClozapineCompletedNCT01015001Phase 3
• Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With SchizophreniaStatus unknownNCT01012830Phase 4
• Internal Monitoring of Eye Movement in SchizophreniaTerminatedNCT01011101
• Screening Protocol for Research ParticipantsCompletedNCT01010620
• Ziprasidone in Early Onset Schizophrenia Spectrum DisordersCompletedNCT01006551Phase 2
• TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in SchizophreniaCompletedNCT01003379Phase 2
• Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following PsychosisCompletedNCT01003132Not applicable
• Schizophrenia Treatment Adherence Investigation (STAI)CompletedNCT01001481
• A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic PatientsCompletedNCT00999895
• Amantadine as Adjunctive Therapy to Antipsychotics in SchizophreniaStatus unknownNCT00999505Phase 3
• Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of SchizophreniaTerminatedNCT00998608Phase 4
• An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With SchizophreniaCompletedNCT00996242Not applicable
• Lifestyle Modification for Weight Loss in SchizophreniaCompletedNCT00990925Not applicable
• Seroquel XR in Schizophrenia Relapse PreventionCompletedNCT00990626
• Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)WithdrawnNCT00988728Phase 2
• The Effects AZD8529 on Cognition and Negative Symptoms in SchizophrenicsCompletedNCT00986531Phase 1
• Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute PsychiatryStatus unknownNCT00986167Phase 4
• Epidemiology of Schizophrenia in BulgariaCompletedNCT00984373
• Effects of Delta-9-THC and Iomazenil in Healthy HumansCompletedNCT00982982Early Phase 1
• Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in CroatiaCompletedNCT00981123
• Medication Adherence in Schizophrenia: Development of a CBT-Based InterventionCompletedNCT00980252Not applicable
• A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of SchizophreniaTerminatedNCT00977522Phase 2
• Safety and Cognitive Function Study of EVP-6124 in Patients With SchizophreniaCompletedNCT00968851Phase 2
• Once Weekly D-cycloserine for SchizophreniaWithdrawnNCT00964041Phase 4
• Huperzine for Cognitive and Functional Impairment in SchizophreniaCompletedNCT00963846Phase 2
• D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic SchizophreniaCompletedNCT00960219Phase 2
• Metabolic Syndrome in Patients With First-episode SchizophreniaCompletedNCT00957294
• Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to QuetiapineCompletedNCT00952757
• Serum Clozapine and CognitionCompletedNCT00951418
• Lamictal TM, Haloperidol Decanoate in SchizophreniaTerminatedNCT00947375Phase 4
• Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.CompletedNCT00945503Phase 1
• Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission TomographyCompletedNCT00942981
• Effectiveness of Family Group Interventions for People With SchizophreniaCompletedNCT00940394Phase 2
• The Study of Atypical Antipsychotics-induced Metabolic DisturbancesCompletedNCT00937755

← Schizophrenia overview